Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Pancreatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Lymphoma, Follicular 3Kidney Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, T-Cell, Cutaneous 2

Interventions

eltrombopag 1durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cytarabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pathologic Complete Response × durvalumab × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡